Biotech’s New Buddy: Private Equity

Good comment from Roger sparked by a BusinessWeek piece claiming that private equity (and hedge funds) has discovered the joy of biotech investing. Granted, it’s mostly biotechs with cash flows so far, but Roger is on the right track in thinking that private equity folks, and hedge funds in particular, get the idea of cheap options much more than venture capitalists do.

That said, hedge funds guys won’t be recruiting CSOs any time soon for the biotech of your choice — a point that Roger glosses. Thena gain, such funds will be than happy to snarff up cheap options in biotechs that traditional VCs are busy avoiding as they race up-market to every-closer to market.